Clinical trials
Localized Prostate Cancer clinical trials
Below are recruiting localized prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 496 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07226713RecruitingPhase 2
Pacritinib for advanced prostate cancer after hormone therapy failure
This trial tests a drug called pacritinib for men with metastatic prostate cancer that has stopped responding to hormone therapies. It aims to see if blocking the JAK2/STAT5 pathway can slow cancer growth.
Milwaukee, WisconsinAges 18 years+ - NCT07538843Recruiting
Darolutamide Plus Hormone Therapy for Prostate Cancer in China
This study watches how well a drug called darolutamide works when combined with hormone therapy for men with prostate cancer that has returned after previous treatment. The goal is to understand if this combination helps prevent cancer spread and is safe to use.
Multiple LocationsAges 18 years+ - NCT06758882RecruitingPhase 2
Surgery with or without apalutamide for high-risk prostate cancer that has spread a little
This trial tests whether adding the drug apalutamide before and after surgery helps men with high-risk prostate cancer that has spread to a few spots (seen on a special PET scan). You would also receive standard hormone therapy.
Torino, ToAges 18–80 - NCT06835426Recruiting
Imaging removed tissue during cancer surgery
This study tests a high-resolution PET-CT scanner that takes pictures of tissue removed during surgery to help doctors see if all the cancer has been removed. You might qualify if you are having surgery for a range of cancers including breast, prostate, thyroid, skin, gastrointestinal, or brain tumors.
Ghent, Oost VlaanderenAges 18 years+ - NCT01913106RecruitingPhase 1/Phase 2
Testing valacyclovir with an added cancer gene in prostate radiation
This Phase 1/2 study tests whether adding a cancer-targeting gene therapy (HSV-tk) and the antiviral medicine valacyclovir to brachytherapy can better treat recurrent prostate cancer in the prostate area. It may help by making cancer cells more vulnerable to the treatment.
Houston, TexasAges Any age - NCT07832292RecruitingPhase 2
Study of an investigational drug for metastatic prostate cancer
This trial tests an experimental drug (JNJ-101556143) for men with metastatic prostate cancer that has stopped responding to hormone therapy. The goal is to see if this drug can slow down or stop the cancer from growing.
Lafayette, LouisianaAges 18 years+ - NCT07364071RecruitingPhase 2
Hormone therapy and targeted radiation for high-risk prostate cancer
This trial tests whether combining standard hormone therapy and radiation with a special targeted radiation (PSMA-targeted radiotherapy) is safe and effective for men with high-risk prostate cancer that hasn't spread outside the pelvis.
La Jolla, CaliforniaAges 18 years+ - NCT07319871RecruitingPhase 1
Study of two drugs for prostate cancer
This trial tests a new combination of two drugs, pasritamig and JNJ-86974680, for men with a certain type of advanced prostate cancer that has spread to bone or lymph nodes but not to organs like the lungs or liver. It aims to see if this combination is safe and effective.
Sarasota, FloridaAges 18 years+ - NCT07082920RecruitingPhase 1
Combination treatment for advanced prostate cancer
This study tests a combination of two new investigational drugs for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drugs aim to help your immune system fight the cancer cells.
Sarasota, FloridaAges 18 years+ - NCT05743621RecruitingPhase 1
First TVB-2640 and enzalutamide for metastatic prostate cancer
This Phase 1 trial tests a new medicine (TVB-2640) combined with enzalutamide in men with prostate cancer that has spread and is no longer responding to hormone treatment. It aims to find a safe dose and see how well the treatment can work against the cancer.
New York, New YorkAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced solid tumors
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Dothan, AlabamaAges 18 years+ - NCT05738187Recruiting
Cryotherapy for repeat head and neck cancer after prior radiation
This pilot study tests whether cooling treatment on the tumor area (cryotherapy) can control a repeat head/neck cancer that can’t be removed and has already been treated with radiation. It also checks safety, especially in areas that have received radiation before.
StrasbourgAges 18 years+ - NCT06862856Recruiting
PET Scan for Men With Very Low PSA After Prostate Surgery
This trial tests a PET scan (flotufolastat F 18) to find tiny prostate cancer cells in men whose PSA is very low but still rising after prostate removal. It may help guide further treatment decisions.
Boston, MassachusettsAges 18 years+ - NCT06161506RecruitingPhase 2
Electrical stimulation for urinary incontinence after prostate cancer treatment
This trial tests a non-surgical, non-drug treatment that uses gentle electrical stimulation on the skin to help strengthen the muscles that control urine leakage. It's for men who still have urinary incontinence at least 6 months after their prostate cancer treatment.
Bethesda, MarylandAges 18–120 - NCT06813898RecruitingEarly Phase 1
A New Scan for Early Prostate Cancer Recurrence
This study tests a new scanning method (rhPSMA-7.3 PET/CT) to detect prostate cancer recurrence when PSA is slightly high. If your PSA is low but rising, and standard scans haven't found cancer, this scan might help locate it.
Chicago, IllinoisAges Any age - NCT04831983Recruiting
Radiation treatment for intermediate- and high-risk prostate cancer
This trial studies a type of focused radiation (“ablative radiotherapy”) for prostate tumors considered intermediate- or high-risk. It may help improve control of the cancer while aiming for acceptable side effects.
Monza, MBAges 18–90 - NCT07693751RecruitingPhase 1/Phase 2
Testing a new drug for advanced colorectal cancer
This trial tests a new drug called SOT109 for people with advanced colorectal cancer that can't be removed by surgery or has spread. The goal is to see if it is safe, how well it works, and how the body handles it.
Houston, TexasAges 18 years+ - NCT05601505RecruitingPhase 2
DNA blood test–guided treatment before rectal cancer surgery
This trial uses a special DNA blood test (circulating tumor DNA) to help guide chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to improve outcomes by tailoring treatment based on the DNA signals from the tumor.
Beijing, Beijing MunicipalityAges 18–75 - NCT06863090Recruiting
Study measuring radiation dose during brachytherapy
This trial tests a way to measure the exact radiation dose you receive during internal radiotherapy (brachytherapy). It aims to make treatment safer and more effective for prostate or gynecologic cancers.
Northwood, MiddlesexAges 18 years+ - NCT07218666RecruitingPhase 2
Zanzalintinib for aggressive prostate cancer
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
Milwaukee, WisconsinAges 18 years+ - NCT07132073Enrolling by invitation
MRI-guided SBRT for high-risk prostate cancer
This study tests a precise radiation treatment for prostate cancer that uses MRI images to guide the radiation beams. It may be an option for men with higher-risk prostate cancer who can have an MRI and have not had radiation before.
Pamplona, Foral Community of NavarreAges 18–80 - NCT02526797Enrolling by invitation
MRI scan study for men on active surveillance
This trial tests how a special MRI scan (with multiple measurements) may help men with low-risk prostate cancer who are monitoring it closely instead of treating right away. It may help doctors better understand the cancer’s status during active surveillance.
HerlevAges 18–75 - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT07224152RecruitingPhase 1/Phase 2
NBTXR3 plus radiation for inoperable lung cancer
This trial tests a new drug called NBTXR3, which makes cancer cells more sensitive to radiation. You'll get one injection of NBTXR3 into your lung tumor, followed by standard radiation. It is for people with early-stage non-small cell lung cancer who cannot have surgery.
Houston, TexasAges 18 years+
Hear when a new Localized Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for localized prostate cancer?
- Yes. Clin2 currently lists 496 recruiting localized prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a localized prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a localized prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.